caf676a4ac
- Source: inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
60 lines
No EOL
2.3 KiB
Markdown
60 lines
No EOL
2.3 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: company
|
|
name: Mark Cuban Cost Plus Drug Company
|
|
founded: 2022
|
|
headquarters: Dallas, TX
|
|
founders: Mark Cuban, Alex Oshmyansky
|
|
status: active
|
|
website: costplusdrugs.com
|
|
domain: health
|
|
tags: [pharmacy, drug-pricing, PBM-alternative, generics, biosimilars]
|
|
---
|
|
|
|
# Mark Cuban Cost Plus Drug Company
|
|
|
|
## Overview
|
|
|
|
Cost Plus Drug Company is a direct-to-consumer pharmacy founded in 2022 by Mark Cuban and Alex Oshmyansky. The company operates on a transparent pricing model: acquisition cost + 15% markup + $3 pharmacy fee + $5 shipping, offering over 2,300 medications (primarily generics).
|
|
|
|
## Business Model
|
|
|
|
**Pricing Structure:**
|
|
- Acquisition cost + 15% fixed fee
|
|
- No insurance intermediation for direct-to-consumer sales
|
|
- Transparent pricing published online
|
|
|
|
**Product Portfolio:**
|
|
- 2,300+ medications (mostly generics)
|
|
- Expanding into biosimilar portfolio
|
|
- Pursuing US manufacturing expansion with generic drug fee waivers
|
|
|
|
**Distribution Strategy:**
|
|
- Partnership with Humana CenterWell Pharmacy for employer prescription solutions (2025)
|
|
- Combines Cost Plus pass-through pricing with CenterWell distribution infrastructure
|
|
- Dependent on incumbent partnerships rather than independent distribution
|
|
|
|
## Market Position
|
|
|
|
**Competitive Context:**
|
|
- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) control ~80% of US prescription claims
|
|
- Cost Plus operates as challenger model coexisting with incumbents
|
|
- Growing market share but partnering with incumbents (Humana) rather than displacing PBMs
|
|
|
|
**Political Role:**
|
|
- Mark Cuban testified at congressional hearings on PBM practices
|
|
- Supported FTC investigations into PBM business practices
|
|
- Functions as political/narrative pressure vehicle even with small market share
|
|
|
|
## Limitations
|
|
|
|
- Primarily generic drugs — does not address branded/biologic drugs where margins are highest
|
|
- No owned distribution infrastructure — dependent on partnerships
|
|
- No clinical services layer — drug pricing tool, not care delivery model
|
|
- Has not achieved meaningful market share in specialty drugs where margin extraction is concentrated
|
|
|
|
## Timeline
|
|
|
|
- **2022** — Company founded by Mark Cuban and Alex Oshmyansky
|
|
- **2025-11** — Partnership announced with Humana CenterWell Pharmacy for employer prescription solutions
|
|
- **2026** — Expanding biosimilar portfolio and pursuing US manufacturing expansion |